A Six-week Double Blinded, Randomized Trial of Atorvastatin for the Treatment of PCOS Women With Elevated LDL Cholesterol

Trial Profile

A Six-week Double Blinded, Randomized Trial of Atorvastatin for the Treatment of PCOS Women With Elevated LDL Cholesterol

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Sep 2014

At a glance

  • Drugs Atorvastatin (Primary)
  • Indications Hyperlipidaemia; Lipid metabolism disorders; Polycystic ovary syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 May 2013 Primary endpoint changed from 'improvement of vascular function' and 'androgen levels' to 'Brachial Artery Flow-mediated Dilation (FMD)'.
    • 07 May 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top